News

GRP Hires Mitchel Allen-Rivera as new Executive Vice President of Business Development

The Greater Richmond Partnership (“GRP”), the lead regional economic development organization serving the City of Richmond and counties of Chesterfield, Hanover and Henrico in Virginia, announces that Mitchel Allen-Rivera is the new Executive Vice President of Business Development.

“I am thrilled to welcome Mitchel to Greater Richmond to lead business development,” said Jennifer Wakefield, President and CEO of the Greater Richmond Partnership. “He is a rockstar economic development professional with a stellar reputation and has repeatedly been recognized among the best in the industry.”

Allen-Rivera is relocating to Greater Richmond, Va., from Phoenix, Ariz., where he has worked as the Senior Vice President of Business Development for the Greater Phoenix Economic Council (GPEC) for nearly a decade in roles of increasing responsibility. In addition to his time at GPEC, he worked at the local level in the City of Chandler, Ariz., and as a manager in the financial services industry.

“I am truly honored to be joining such an exceptional team of professionals under Jennifer Wakefield’s leadership,” said Allen-Rivera. “Richmond is an amazing community full of talent and I am eager to contribute to the region’s future development.”

Allen-Rivera has a bachelor’s degree in communication from Arizona State University and is currently pursuing a master of business administration (MBA) from the University of Denver. He has been recognized twice among the Top 50 economic developers in North America by Consultant Connect, been named as a top 40 under 40 professional in economic development by Development Counsellors International and the International Economic Development Council and as Economic Developer of the Year by the Arizona Association for Economic Development.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients